Cargando…
Aterofisiol(®) in carotid plaque evolution
BACKGROUND: In patients with carotid stenosis, the risk of plaque rupture is related to the composition of the atherosclerotic plaque rather than to its magnitude. In this regard, we evaluated the effects of a supplement, Aterofisiol,(®) containing omega-3 (EPA [eicosapen acid] DHA [docosahexaenoic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517514/ https://www.ncbi.nlm.nih.gov/pubmed/26229448 http://dx.doi.org/10.2147/DDDT.S87609 |
_version_ | 1782383200268451840 |
---|---|
author | Amato, Bruno Compagna, Rita Amato, Maurizio Gallelli, Luca de Franciscis, Stefano Serra, Raffaele |
author_facet | Amato, Bruno Compagna, Rita Amato, Maurizio Gallelli, Luca de Franciscis, Stefano Serra, Raffaele |
author_sort | Amato, Bruno |
collection | PubMed |
description | BACKGROUND: In patients with carotid stenosis, the risk of plaque rupture is related to the composition of the atherosclerotic plaque rather than to its magnitude. In this regard, we evaluated the effects of a supplement, Aterofisiol,(®) containing omega-3 (EPA [eicosapen acid] DHA [docosahexaenoic acid]), vitamin K(2), vitamin B(6), vitamin B(12), oligomeric proanthocyanidins (OPC) and resveratrol on the composition of atherosclerotic plaque and on neurological symptoms in patients with carotid stenosis undergoing carotid endarterectomy. METHODS: The study was randomized, prospective, and double-blinded. Eligible patients were of both sexes, with carotid stenosis >70% who underwent endarterectomy. Enrolled patients were randomly allocated to receive either one tablet of acetylsalicylic acid 100 mg (Cardioaspirin(®)) + one tablet of Aterofisiol every 24 hours or one tablet of Cardioaspirin + one tablet of placebo every 24 hours. Each treatment was started 30 days before the surgery and was stopped 5 days before the surgery. The plaques were removed “en bloc” using standard surgical technique. RESULTS: During the study period, 214 patients (135 men and 79 women) were enrolled for intent-to-treat and randomized in two groups: Group A: 107 patients (68 men and 39 women) were treated with Cardioaspirin + Aterofisiol. Group B: 107 patients (67 men and 40 women) were treated with Cardioaspirin + placebo. At the end of the study, 202 patients participated fully (103 patients in Group A and 99 patients in Group B), making up the protocol evaluation population (94.4%). The mean lipid content of removed plaques was significantly lower (P<0.05) in Group A. We recorded a significantly lower incidence of neurological symptoms in Group A in comparison with Group B (P<0.05). CONCLUSION: In the study, Aterofisiol showed to be effective in reducing the amounts of cholesterol and lipids in the plaques and in reducing adverse neurological events in the study group with respect to controls. |
format | Online Article Text |
id | pubmed-4517514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45175142015-07-30 Aterofisiol(®) in carotid plaque evolution Amato, Bruno Compagna, Rita Amato, Maurizio Gallelli, Luca de Franciscis, Stefano Serra, Raffaele Drug Des Devel Ther Original Research BACKGROUND: In patients with carotid stenosis, the risk of plaque rupture is related to the composition of the atherosclerotic plaque rather than to its magnitude. In this regard, we evaluated the effects of a supplement, Aterofisiol,(®) containing omega-3 (EPA [eicosapen acid] DHA [docosahexaenoic acid]), vitamin K(2), vitamin B(6), vitamin B(12), oligomeric proanthocyanidins (OPC) and resveratrol on the composition of atherosclerotic plaque and on neurological symptoms in patients with carotid stenosis undergoing carotid endarterectomy. METHODS: The study was randomized, prospective, and double-blinded. Eligible patients were of both sexes, with carotid stenosis >70% who underwent endarterectomy. Enrolled patients were randomly allocated to receive either one tablet of acetylsalicylic acid 100 mg (Cardioaspirin(®)) + one tablet of Aterofisiol every 24 hours or one tablet of Cardioaspirin + one tablet of placebo every 24 hours. Each treatment was started 30 days before the surgery and was stopped 5 days before the surgery. The plaques were removed “en bloc” using standard surgical technique. RESULTS: During the study period, 214 patients (135 men and 79 women) were enrolled for intent-to-treat and randomized in two groups: Group A: 107 patients (68 men and 39 women) were treated with Cardioaspirin + Aterofisiol. Group B: 107 patients (67 men and 40 women) were treated with Cardioaspirin + placebo. At the end of the study, 202 patients participated fully (103 patients in Group A and 99 patients in Group B), making up the protocol evaluation population (94.4%). The mean lipid content of removed plaques was significantly lower (P<0.05) in Group A. We recorded a significantly lower incidence of neurological symptoms in Group A in comparison with Group B (P<0.05). CONCLUSION: In the study, Aterofisiol showed to be effective in reducing the amounts of cholesterol and lipids in the plaques and in reducing adverse neurological events in the study group with respect to controls. Dove Medical Press 2015-07-23 /pmc/articles/PMC4517514/ /pubmed/26229448 http://dx.doi.org/10.2147/DDDT.S87609 Text en © 2015 Amato et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Amato, Bruno Compagna, Rita Amato, Maurizio Gallelli, Luca de Franciscis, Stefano Serra, Raffaele Aterofisiol(®) in carotid plaque evolution |
title | Aterofisiol(®) in carotid plaque evolution |
title_full | Aterofisiol(®) in carotid plaque evolution |
title_fullStr | Aterofisiol(®) in carotid plaque evolution |
title_full_unstemmed | Aterofisiol(®) in carotid plaque evolution |
title_short | Aterofisiol(®) in carotid plaque evolution |
title_sort | aterofisiol(®) in carotid plaque evolution |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517514/ https://www.ncbi.nlm.nih.gov/pubmed/26229448 http://dx.doi.org/10.2147/DDDT.S87609 |
work_keys_str_mv | AT amatobruno aterofisiolincarotidplaqueevolution AT compagnarita aterofisiolincarotidplaqueevolution AT amatomaurizio aterofisiolincarotidplaqueevolution AT gallelliluca aterofisiolincarotidplaqueevolution AT defranciscisstefano aterofisiolincarotidplaqueevolution AT serraraffaele aterofisiolincarotidplaqueevolution |